drugset / Trial / NCT01401985

A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

NCT01401985

Phase 2 Completed 95 enrolled Glycyx Therapeutics Theravance Biopharma · collab
Non-randomizedSequentialSingle-blindTreatment

Summary

A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects with Opioid-Induced Constipation

Timeline

Start
2011-10
Primary completion
2012-05
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject axelopran Small molecule 2 mg
Subject axelopran Small molecule 2.5 mg
Subject axelopran Small molecule 10 mg
Subject axelopran Small molecule 15 mg